On ECHEMI
Home > Drugs > Pancreatic cancer
Pancreatic cancer
Pancreatic carcinoma is a common pancreatic tumor. It is a highly malignant digestive tract tumor that is difficult to diagnose and treat. About 90% of pancreatic cancers are ductal adenocarcinomas that originate from the glandular duct epithelium. Its morbidity and mortality rates have increased significantly in recent years. The 5-year survival rate is less than 1%, making it one of the malignant tumors with the worst prognosis. The early diagnosis rate of pancreatic cancer is not high, the surgical mortality rate is high, and the cure rate is very low. The incidence of this disease is higher in men than in women, with a male-to-female ratio of 1.5 to 2:1. Male patients are much more common than premenopausal women, and the incidence rate of postmenopausal women is similar to that of men.
  • Site of disease:

    pancreas
  • Infectious :

    Not contagious
  • Frequent population:

    Adult women and breastfeeding women are more likely to get
  • Related symptoms:

    Upper abdominal pain Upper abdominal mass and bloating Transverse colon displacement Fatigue Weight loss
Related Drugs
Xiaoaiping Granules
Manufacturer:

Shanghai Huangxiang Tieli Blue Sky Pharmaceutical Co., Ltd.

Uracil Tegafur Tablets
Indication: It is used for digestive tract cancers such as stomach cancer, intestinal cancer, pancreatic cancer, and can also be used for breast cancer and primary liver cancer. Taking the medicine before and after surgery may prevent the recurrence, spread, and metastasis of cancer.
Manufacturer:

RenHe Hetero Pharmaceuticals Ltd.

Uracil Tegafur Tablets
Indication: It is used for digestive tract cancers such as stomach cancer, intestinal cancer, pancreatic cancer, and can also be used for breast cancer and primary liver cancer. Taking the medicine before and after surgery may prevent the recurrence, spread, and metastasis of cancer.
Uracil Tegafur Capsules
Indication: Used for digestive tract tumors, such as gastric cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, etc., as well as head and neck cancer, lung cancer, and breast cancer.
Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:

Qilu Pharmaceutical (Hainan) Co., Ltd.

Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:

Harbin Pharmaceutical Group Bioengineering Co., Ltd.

Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:

Harbin Pharmaceutical Group Bioengineering Co., Ltd.

Gemcitabine Hydrochloride for Injection
Indication: Suitable for the treatment of intermediate and advanced non-small cell lung cancer.
Manufacturer:

Harbin Reputation Scale Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.